Skip to main content

Table 3 At risk genotype’s counts by drug/therapy class

From: Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations

Class number Drug class At risk genotype At risk genotype count Samples Genotype frequency
1 Fluoropyrimidines
 rs2297595 + rs1048943 + rs3918290 CC + CT & TT & TT + CT 0 1581 0
 rs2297595 + rs1048943 CC + CT & TT 20 1581 1.26 %
 rs2297595 + rs3918290 CC + CT & TT + CT 1 1581 0.06 %
 rs1048943 + rs3918290 TT & TT + CT 1 1581 0.06 %
2 Alkylating agents
 rs4880 + rs4244285 GA + GG & AA 4 331 1.20 %
3 Monoclonal antibodies
 rs1136201 + rs1801274 GA & GG + GA 291 1581 18.40 %
  1. Out of six classes, members of three of them (i.e., the breast cancer medications) did not share any of the reported at risk genotype. For class 1, three SNPs related with Fluoropyrimidines were found and different combinations are reported. Drug class class of drugs or treatment, At risk genotype risk genotype for the class, At risk genotype count count of joint risk genotypes for the class, Samples total number of analyzed samples, Genotype frequency at risk genotype frequency